Co-Authors
This is a "connection" page, showing publications co-authored by Alimuddin Zumla and Giovanni Sotgiu.
Connection Strength
2.684
-
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S96-S99.
Score: 0.467
-
COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020 08 01; 24(8):757-760.
Score: 0.448
-
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018 07; 18(7):e183-e198.
Score: 0.380
-
Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". Int J Infect Dis. 2018 03; 68:122-124.
Score: 0.380
-
De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing. Int J Infect Dis. 2017 Mar; 56:34-38.
Score: 0.351
-
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. J Bras Pneumol. 2018 Apr; 44(2):153-160.
Score: 0.190
-
Tuberculosis series. J Bras Pneumol. 2018 04; 44(2):71-72.
Score: 0.190
-
World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. Int J Infect Dis. 2017 03; 56:1-5.
Score: 0.176
-
Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
Score: 0.057
-
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017 05; 49(5).
Score: 0.045